The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Important considerations when treating IDH-mutated AML: managing combination regimens
In this video, Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses practical considerations when treating patients with IDH-mutated acute myeloid leukemia (AML). She emphasizes the importance of managing cumulative toxicities and adjusting the duration of therapy based on patient tolerability and cytopenias. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
